N

ovartis’ groundbreaking CAR-T cancer therapy is one big step closer to reaching patients.

A panel of outside experts convened by the FDA voted 10-0 Wednesday to recommend the approval of Novartis’ CAR-T therapy, called CTL019, for the treatment of children and young adults with advanced leukemia. The vote marks a pivotal milestone for this class of experimental treatment. The FDA is expected to make a final decision on approval by Oct. 3.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • You should know the truth about CANCER. There are so many different therapies & drugs out there, far better to avoid Cancer. Spirit know what causes CANCER so people are not confused about it.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.